Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Abie Horowitz

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Therapeutic Advances in Psychopharmacology|July 17, 2020
Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorderJoanna Moncrieff, Swapnil Gupta, Mark Abie Horowitz
The Lancet. Psychiatry|June 19, 2022
Unbalanced appraisal of psychosocial versus antipsychotic literatureMark Abie Horowitz, Klaus Munkholm, Joanna Moncrieff
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With SchizophreniaMark Abie Horowitz, Alex Macaulay, David Taylor
Addictive Behaviors|May 1, 2021
Should gabapentinoids be prescribed long-term for anxiety and other mental health conditions?Mark Abie Horowitz, Michael Kelleher, David Taylor
Journal of Psychiatric Research|March 29, 2023
Designing withdrawal support services for antidepressant users: Patients' views on existing services and what they really needJohn Read, Joanna Moncrieff, Mark Abie Horowitz
JAMA|June 1, 2021
Risks and Benefits of BenzodiazepinesMark Abie Horowitz, James M Wright, David Taylor
Schizophrenia Bulletin|December 29, 2021
Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related RelapseMark Abie Horowitz, Robin M Murray, David Taylor
The Lancet. Psychiatry|August 22, 2021
Withdrawal-associated relapse is a potential source of biasMark Abie Horowitz, Robin M Murray, David Taylor
JAMA Psychiatry|August 11, 2020
Tapering Antipsychotic TreatmentMark Abie Horowitz, Robin M Murray, David Taylor
Schizophrenia Bulletin|September 19, 2025
Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be ImportantMark Abie Horowitz, James O'Neill, Fabrice Berna, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Psychopharmacology|July 17, 2020
Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorderJoanna Moncrieff, Swapnil Gupta, Mark Abie Horowitz
The Lancet. Psychiatry|June 19, 2022
Unbalanced appraisal of psychosocial versus antipsychotic literatureMark Abie Horowitz, Klaus Munkholm, Joanna Moncrieff
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With SchizophreniaMark Abie Horowitz, Alex Macaulay, David Taylor
Addictive Behaviors|May 1, 2021
Should gabapentinoids be prescribed long-term for anxiety and other mental health conditions?Mark Abie Horowitz, Michael Kelleher, David Taylor
Journal of Psychiatric Research|March 29, 2023
Designing withdrawal support services for antidepressant users: Patients' views on existing services and what they really needJohn Read, Joanna Moncrieff, Mark Abie Horowitz
JAMA|June 1, 2021
Risks and Benefits of BenzodiazepinesMark Abie Horowitz, James M Wright, David Taylor
Schizophrenia Bulletin|December 29, 2021
Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related RelapseMark Abie Horowitz, Robin M Murray, David Taylor
The Lancet. Psychiatry|August 22, 2021
Withdrawal-associated relapse is a potential source of biasMark Abie Horowitz, Robin M Murray, David Taylor
JAMA Psychiatry|August 11, 2020
Tapering Antipsychotic TreatmentMark Abie Horowitz, Robin M Murray, David Taylor
Schizophrenia Bulletin|September 19, 2025
Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be ImportantMark Abie Horowitz, James O'Neill, Fabrice Berna, et al.
Pageof 3